v3.26.1
Cover - USD ($)
12 Months Ended
Dec. 31, 2025
Apr. 14, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 000-56257    
Entity Registrant Name ACCUSTEM SCIENCES, INC.    
Entity Central Index Key 0001850767    
Entity Tax Identification Number 87-3774438    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 420 Lexington Avenue    
Entity Address, Address Line Two Suite 1402    
Entity Address, City or Town NY    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10001    
City Area Code 00 44    
Local Phone Number 2074952379    
Title of 12(b) Security Common Stock    
Trading Symbol ACUT    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 9,684,334
Entity Common Stock, Shares Outstanding   16,072,267  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.001    
Auditor Firm ID 3223    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of AccuStem Sciences Inc. and its subsidiary (the “Company”) as of December 31, 2025, and 2024, the related consolidated statements of operations, changes in shareholders’ equity/(deficit) and cash flows, for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name Mercurius & Associates LLP    
Auditor Location New Delhi, India